Skip to main content

Drug Safety

      On the first day of EULAR 2024, I am debating Janet Pope. To make it more challenging, it’s about JAK inhibitor safety, and I have been allocated to argue against the regulatory safety warning…
      Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years…
      ×